Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
23
BTAI Quote, Financials, Valuation and Earnings
Last price:
$1.60
Seasonality move
:
59.54%
Day range:
$1.52 - $1.60
52-week range:
$1.17 - $9.26
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
15.91x
P/B ratio:
--
Volume:
540.7K
Avg. volume:
521K
1-year change:
-73.25%
Market cap:
$35M
Revenue:
$2.3M
EPS (TTM):
-$9.70
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BTAI
BioXcel Therapeutics, Inc.
|
$166.7K | -$0.85 | -54.46% | -76.21% | $16.75 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.37 | -- | -94.42% | $7.00 |
|
XLO
Xilio Therapeutics, Inc.
|
$8M | $0.37 | 361.72% | -65.63% | $4.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BTAI
BioXcel Therapeutics, Inc.
|
$1.60 | $16.75 | $35M | -- | $0.00 | 0% | 15.91x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$5.64 | $0.85 | $710.7M | 9.47x | $0.80 | 0% | 10.96x |
|
OGEN
Oragenics, Inc.
|
$0.78 | $2.00 | $644.5K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.21 | $7.00 | $7.1M | -- | $0.00 | 0% | 0.33x |
|
XLO
Xilio Therapeutics, Inc.
|
$0.64 | $4.00 | $33.6M | -- | $0.00 | 0% | 1.91x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BTAI
BioXcel Therapeutics, Inc.
|
536.58% | 2.291 | 213.49% | 0.99x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -3.190 | 8.08% | 1.85x |
|
OGEN
Oragenics, Inc.
|
3.86% | 0.905 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -2.522 | 66.16% | 0.68x |
|
XLO
Xilio Therapeutics, Inc.
|
-872.96% | 1.304 | 16.63% | 2.15x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BTAI
BioXcel Therapeutics, Inc.
|
$12K | -$13.9M | -512.4% | -- | -14212.25% | -$18.8M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
|
XLO
Xilio Therapeutics, Inc.
|
$18.7M | -$1.9M | -334.24% | -606.15% | -10.12% | -$17.5M |
BioXcel Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns BTAI or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -31541.84% compared to BioXcel Therapeutics, Inc.'s net margin of -255.85%. BioXcel Therapeutics, Inc.'s return on equity of -- beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital BTAIBioXcel Therapeutics, Inc.12.25% -$2.18 $20.4M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About BTAI or NBY?
BioXcel Therapeutics, Inc. has a consensus price target of $16.75, signalling upside risk potential of 946.88%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -84.93%. Given that BioXcel Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe BioXcel Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BTAIBioXcel Therapeutics, Inc.3 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is BTAI or NBY More Risky?
BioXcel Therapeutics, Inc. has a beta of 0.213, which suggesting that the stock is 78.742% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.
-
Which is a Better Dividend Stock BTAI or NBY?
BioXcel Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. BioXcel Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BTAI or NBY?
BioXcel Therapeutics, Inc. quarterly revenues are $98K, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. BioXcel Therapeutics, Inc.'s net income of -$30.9M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, BioXcel Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 9.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXcel Therapeutics, Inc. is 15.91x versus 10.96x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BTAIBioXcel Therapeutics, Inc.15.91x -- $98K -$30.9M NBYNovaBay Pharmaceuticals, Inc.10.96x 9.47x $521K -$1.3M
-
Which has Higher Returns BTAI or OGEN?
Oragenics, Inc. has a net margin of -31541.84% compared to BioXcel Therapeutics, Inc.'s net margin of --. BioXcel Therapeutics, Inc.'s return on equity of -- beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital BTAIBioXcel Therapeutics, Inc.12.25% -$2.18 $20.4M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About BTAI or OGEN?
BioXcel Therapeutics, Inc. has a consensus price target of $16.75, signalling upside risk potential of 946.88%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 155.36%. Given that BioXcel Therapeutics, Inc. has higher upside potential than Oragenics, Inc., analysts believe BioXcel Therapeutics, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BTAIBioXcel Therapeutics, Inc.3 0 0 OGENOragenics, Inc.1 0 0 -
Is BTAI or OGEN More Risky?
BioXcel Therapeutics, Inc. has a beta of 0.213, which suggesting that the stock is 78.742% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.685%.
-
Which is a Better Dividend Stock BTAI or OGEN?
BioXcel Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioXcel Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BTAI or OGEN?
BioXcel Therapeutics, Inc. quarterly revenues are $98K, which are larger than Oragenics, Inc. quarterly revenues of --. BioXcel Therapeutics, Inc.'s net income of -$30.9M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, BioXcel Therapeutics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXcel Therapeutics, Inc. is 15.91x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BTAIBioXcel Therapeutics, Inc.15.91x -- $98K -$30.9M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns BTAI or PTN?
Palatin Technologies has a net margin of -31541.84% compared to BioXcel Therapeutics, Inc.'s net margin of --. BioXcel Therapeutics, Inc.'s return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BTAIBioXcel Therapeutics, Inc.12.25% -$2.18 $20.4M PTNPalatin Technologies-- -- -- -
What do Analysts Say About BTAI or PTN?
BioXcel Therapeutics, Inc. has a consensus price target of $16.75, signalling upside risk potential of 946.88%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than BioXcel Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than BioXcel Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BTAIBioXcel Therapeutics, Inc.3 0 0 PTNPalatin Technologies0 0 0 -
Is BTAI or PTN More Risky?
BioXcel Therapeutics, Inc. has a beta of 0.213, which suggesting that the stock is 78.742% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock BTAI or PTN?
BioXcel Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioXcel Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BTAI or PTN?
BioXcel Therapeutics, Inc. quarterly revenues are $98K, which are larger than Palatin Technologies quarterly revenues of --. BioXcel Therapeutics, Inc.'s net income of -$30.9M is higher than Palatin Technologies's net income of --. Notably, BioXcel Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXcel Therapeutics, Inc. is 15.91x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BTAIBioXcel Therapeutics, Inc.15.91x -- $98K -$30.9M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns BTAI or TOVX?
Theriva Biologics, Inc. has a net margin of -31541.84% compared to BioXcel Therapeutics, Inc.'s net margin of --. BioXcel Therapeutics, Inc.'s return on equity of -- beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital BTAIBioXcel Therapeutics, Inc.12.25% -$2.18 $20.4M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About BTAI or TOVX?
BioXcel Therapeutics, Inc. has a consensus price target of $16.75, signalling upside risk potential of 946.88%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3227%. Given that Theriva Biologics, Inc. has higher upside potential than BioXcel Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than BioXcel Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BTAIBioXcel Therapeutics, Inc.3 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is BTAI or TOVX More Risky?
BioXcel Therapeutics, Inc. has a beta of 0.213, which suggesting that the stock is 78.742% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.729%.
-
Which is a Better Dividend Stock BTAI or TOVX?
BioXcel Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioXcel Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BTAI or TOVX?
BioXcel Therapeutics, Inc. quarterly revenues are $98K, which are larger than Theriva Biologics, Inc. quarterly revenues of --. BioXcel Therapeutics, Inc.'s net income of -$30.9M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, BioXcel Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXcel Therapeutics, Inc. is 15.91x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BTAIBioXcel Therapeutics, Inc.15.91x -- $98K -$30.9M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
-
Which has Higher Returns BTAI or XLO?
Xilio Therapeutics, Inc. has a net margin of -31541.84% compared to BioXcel Therapeutics, Inc.'s net margin of -85.42%. BioXcel Therapeutics, Inc.'s return on equity of -- beat Xilio Therapeutics, Inc.'s return on equity of -606.15%.
Company Gross Margin Earnings Per Share Invested Capital BTAIBioXcel Therapeutics, Inc.12.25% -$2.18 $20.4M XLOXilio Therapeutics, Inc.98.22% -$0.11 -$832K -
What do Analysts Say About BTAI or XLO?
BioXcel Therapeutics, Inc. has a consensus price target of $16.75, signalling upside risk potential of 946.88%. On the other hand Xilio Therapeutics, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 212.4%. Given that BioXcel Therapeutics, Inc. has higher upside potential than Xilio Therapeutics, Inc., analysts believe BioXcel Therapeutics, Inc. is more attractive than Xilio Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BTAIBioXcel Therapeutics, Inc.3 0 0 XLOXilio Therapeutics, Inc.1 0 0 -
Is BTAI or XLO More Risky?
BioXcel Therapeutics, Inc. has a beta of 0.213, which suggesting that the stock is 78.742% less volatile than S&P 500. In comparison Xilio Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BTAI or XLO?
BioXcel Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xilio Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioXcel Therapeutics, Inc. pays -- of its earnings as a dividend. Xilio Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BTAI or XLO?
BioXcel Therapeutics, Inc. quarterly revenues are $98K, which are smaller than Xilio Therapeutics, Inc. quarterly revenues of $19.1M. BioXcel Therapeutics, Inc.'s net income of -$30.9M is lower than Xilio Therapeutics, Inc.'s net income of -$16.3M. Notably, BioXcel Therapeutics, Inc.'s price-to-earnings ratio is -- while Xilio Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXcel Therapeutics, Inc. is 15.91x versus 1.91x for Xilio Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BTAIBioXcel Therapeutics, Inc.15.91x -- $98K -$30.9M XLOXilio Therapeutics, Inc.1.91x -- $19.1M -$16.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 1
Corcept Therapeutics, Inc. [CORT] is down 50.44% over the past day.
Buy
75
AXSM alert for Jan 1
Axsome Therapeutics, Inc. [AXSM] is up 22.82% over the past day.
Buy
81
ZIJMY alert for Jan 1
Zijin Mining Group Co., Ltd. [ZIJMY] is up 1.86% over the past day.
